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1. Introduction   
Systemic lupus erythematosus (SLE) is a wide spectrum disease with many clinical 
manifestations. Lack of awareness of the disease itself, with its common and rare 
presentations results in significant delay in diagnosis and consequently serious compromise 
of patients’ care.  
Physical examination will always retain its importance as the most common diagnostic test 
used by doctors and as an essential tool for modern practice(Joshua, Celermajer et al. 2005). 
Findings from proper musculoskeletal (MSK) examination is extremely useful in diagnosing 
rheumatologic disorders especially where gold standard diagnostic tests are lacking. From 
this perspective there should be much emphasis on basic bedside skills among clinicians 
searching for arthritis. Asking about morning stiffness and joint swelling are simple enough 
to pick up early arthritis (Paget 2007). Performing an active range of motion testing of joints 
as a screening method would pick up limitations in joints mobility from active arthritis. In 
real practice, the picture is not simple as such. Despite the impact of MSK disorders on 
health care, rheumatological diseases are often overlooked or inadequately assessed by 
doctors (Jones, Maddison et al. 1992). This chapter will explore some of the issues around 
this complex clinical and educational problem. 
SLE  (the disease of thousand faces) is not only affecting the joints. Major organ involvement 
can be the first presenting symptom(s) and/or sign(s). Knowledge of some of the common 
presenting features of SLE apart from arthritis would help greatly in early recognition of 
this multisystem disease. Renal, central nervous system (CNS), and cardiovascular system 
(CVS) are commonly affected in SLE patients. Knowing the risk factors, early detection and 
close folllow up will have positive impact on patient’s outcome. This chapter will discuss 
some of the clinical issues arising while managing SLE patients that are commonly 
overlooked by clinicans. Late onset SLE and other rare associations like Kikuchi Fujimoto 
disease  will be disscussed in this chapter as well.  
2. Deficiencies in musculoskeletal examination skills 
MSK symptoms are the most common health complications that require medical attention, 
accounting to 20% of both primary care and emergency-room visits (Rasker 1995).  In a 
health survey, MSK disorders were ranked first in prevalence as the cause of chronic health 
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problems, long term disabilities, and consultations with a health professional (Badley, 
Rasooly et al. 1994). In Saudi Arabia, MSK disorders is the second major cause of outpatients 
visit in primary care centers and private clinics (MOH 2009). A number of different medical 
specialties are involved in treating patients with musculoskeletal complaints, including 
general practitioners, family physicians, internists, orthopedic and surgeons, working in 
teams with other health professionals, but often without a multispecialty focus. In order to 
truly improve the outcome of treatment for musculoskeletal conditions, it is important that 
experts in the various specialties work more closely together and look for commonality of 
approach, as they often treat the same patients but from different angles.  
Despite the high prevalence of musculoskeletal disorders in all fields of clinical practice, 
studies show a lower level of competence and confidence in MSK cognitive and clinical 
skills (including physical examinations) across clinicians (Akesson, Dreinhofer et al. 2003; 
Almoallim, Khojah et al. 2007; Beattie, Bobba et al. 2008).  Also, a continuous neglect of 
musculoskeletal examination skills in clinical practice is observed. We reported a case of SLE 
with active arthritis where the diagnosis was delayed for seven days after hospital 
admission due to the lack of basic skills in MSK examination (Almoallim, Khojah et al. 2007). 
The patient in the report presented to the emergency room with fever and pancytopenia and 
apparently the focus of the treating medical team was mainly on these presenting findings. 
This might had restricted the clerking done on admission to "hematology and infectious 
diseases" while what should had been done was a complete history and thorough physical 
examination regardless of initial impression. Musculoskeletal assessment should be a part of 
routine clerking (Lillicrap, Byrne et al. 2003). Assuring such attitude among clinicians will 
prevent unnecessary delay in diagnosis. If a simple musculoskeletal screening examination 
focused mainly on range of motion testing to assess function was done, this patient's active 
arthritis would have been picked up on admission. This would have initiated early search 
for a rheumatological disease and start treatment without a delay. 
  Despite this impact of MSK disorders on health care, rheumatological diseases are often 
overlooked or inadequately assessed by doctors (Jones, Maddison et al. 1992). Thus, patients 
with complaints about bones and joints are often ignored and their problems 
underestimated by doctors.  In a study among 200 general medical inpatients in a teaching 
hospital, it was found out that the signs and symptoms of MSK disorder which were 
recorded in the hospital notes was only 5.5% and 14% respectively. This compared poorly 
with recorded examinations of other systems and regions for example, cardiovascular 
symptoms were recorded in 100% of the cases; respiratory and abdominal symptoms were 
recorded in 99%,  the nervous system , skin and female breasts symptoms were recorded in 
77% and 13% respectively (Doherty, Abawi et al. 1990). In another report, only 40%of 
patients admitted to general medicine ward  had the history of their MSK symptoms 
recorded and only 14.5% of these patients received comprehensive MSK examination 
(Ahern, Soden et al. 1991).  Furthermore, 80% of symptomatic patients received either no 
treatment for their rheumatic disorders, or treatment that was regarded as suboptimal or 
inappropriate (Ahern, Soden et al. 1991). Another report showed even a higher percentage 
of patients – 63% of all patient admitted to general medicine ward- had MSK symptoms or 
its signs, but relevant MSK history was missed in 49% of the patients records, while signs 
were missed in 78%; 42% of those with MSK conditions would have benefitted from 
additional treatment (Lillicrap, Byrne et al. 2003). A more recent report reviewed 150 patient 
notes in three different hospitals from the acute admission wards for medicine and surgery 
and the medical assessment unit. Factors considered included whether GALS screenings 
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had taken place, documentation of MSK examinations and assessment of confidence of 
junior doctors in assessing MSK conditions. GALS screenings were performed in 4% of 
patients on the medical assessment unit, 7% in acute medical and 0% in acute surgical 
patients on admission. Examination of the MSK system yielded better results with 16%, 22% 
and 10% on each of the respective wards. Interviews with junior doctors found 10% 
routinely screening for MSK conditions, despite 87% feeling confident in taking MSK 
histories (Sirisena, Begum et al.). 
Matzkin et al. (2005) indicated that the majority (79%) of the study respondents including 
medical students, residents, and staff physicians failed the basic MSK cognitive examination. 
This suggests that training in MSK medicine is inadequate in both medical school and in  most 
residency training programs. Worldwide, undergraduate and postgraduate medical 
teaching of MSK disorders is currently brief and not directly relevant to the knowledge and 
skills commonly required for the management of these conditions in an outpatient setting.  
In undergraduate education, inadequate MSK education has been reported. Medical 
students spend very few hours on the MSK system, both in basic science and in clinical 
training. It is quite common for students to leave medical schools without being able to 
make a general assessment of the musculoskeletal system. On the other hand, it would be 
considered a total neglect if a medical graduate is incompetent at adequately assessing the 
heart or lungs. Harvard medical students have reported general dissatisfaction of their 
confidences in examining MSK system as compared to their skills in examining pulmonary 
system (Day, YEh et al. 2007). They suggested more time to be devoted to MSK medicine 
and more integration between pre-medical and clinical courses.  
The American Association of Medical Colleges claims that most medical schools do not 
effectively educate future physicians on MSK medicine in spite of the increasing prevalence 
of MSK conduction across medical practice ((AAMC) 2005). The obvious discrepancy 
between the magnitude of MSK conditions and physicians competences, which mostly 
stemmed from the educational deficiencies at the medical schools, is maintained across 
years ((AAMC) 2005; Day, YEh et al. 2007; Clark, Hutchison et al. 2010). Akesson and 
colleagues (2003) argued that teaching at the undergraduate and graduate programmes is 
not adequate and the resulting competence does not reflect the impact of these conditions on 
individuals and society. A comprehensive study reviewing the curricula of all Canadian 
medical schools indicated that directors of undergraduate MSK programmes felt dissatisfied  
with the curricular time devoted to MSK education (Pinney and Regan 2001). In a 
comprehensive study based on a national survey in Saudi Arabia using the Delphi 
technique, internal medicine knowledge and skills competencies including rheumatology 
were determined and prioritized (Almoallim 2010). Table 1 represents only rheumatological 
skills competencies that were identified. Note that the score of 3: indicates must know the 
topic, 2: should know the topic, 1: interesting to know the topic. It was decided in this 
research that any competency with a score ≥ 2.2 should be considered a core competency. 
Table 2 represents overall disease ratings with the number of competencies identified for 
each disease. Such findings would help greatly in designing educational programmes and 
assessment methods based on priorities and it will help in determining what skills for 
rheumatological diseases should be taught. It is a common recommendation among experts 
to give proper attention to training in MSK conditions for both undergraduate and 
postgraduate training programmes.  
In the postgraduate programme the same limitation was highlighted since the 1980s: 
Goldenberg et al (1985) reported that the majority of directors of residency programs 
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thought that many basic skills and techniques were not taught adequately and that the 
training of their rheumatology residents was not equal to that of residents in cardiology or 
gastroenterology. General dissatisfactions of MSK training was reported among the internal 
medicine residents and family practice. United States residents expressed their 
dissatisfaction of their  competence in performing MSK examinations at various parts of the 
body and revealed that to the inadequate or poor training (Clawson, Jackson et al. 2001).  
2.1 Possible obstacles toward an appropriate MSK medical practice  
Previous studies suggested many reasons related to MSK poor clinical skills and physical 
examinations in particular (Clawson, Jackson et al. 2001; Akesson, Dreinhofer et al. 2003; 
(AAMC) 2005; Matzkin, Smith et al. 2005; Day, YEh et al. 2007; Dequeker, Esselens et al. 
2007; Thompson 2008; MOH 2009; Clark, Hutchison et al. 2010):   
 Vague training of MSK in undergraduate programmes;  
 Underestimate the prevalence of MSK conditions and its impact on individuals and 
society  
 MSK is not considered as main competence among medical graduates because it is not a 
life threatening condition.  
 Number of different specialties  involved in treating patients with MSK conditions  do 
not share common approach regardless of specialties interventions, 
 Lack of a proper teaching in MSK is essential in the low competence in MSK generally 
and physical examinations  
 Lack of summative evaluation of MSK physical examination contributes to medical 
graduate low level of competencies  
 The lack of holistic approach and the focus of specialties  
 The lack of standardize approach to the clinical assessment of MSK problems whether 
presenting to primary care, rheumatology or orthopedics that give a benchmark for this 
competency.  
 The disparity in the approach to examination between rheumatologists and orthopaedic 
surgeons mostly leads to poor performances in MSK physical examinations  
 The lack of appropriate teaching and evaluation of MSK because the physical 
examination teachers are not skilled in MSK examinations and thus bone and joint 
diseases are not screened. 
2.2 Global initiative toward MSK medicine  
The global initiative to disseminate awareness to MSK wellbeing had made the World 
Health Organization (WHO) designate the years 2000 to 2010 as Bone and Joint Decade 
(Lidren 2003). In the light of the worldwide commitment, the focus increases on the 
responsibility of medical education and training programmes in providing adequate 
musculoskeletal education. Therefore, global consensus among international experts from 
different specialties and organizations developed a recommendation for MSK teaching in 
undergraduate medical education (Woolf, WAlsh et al. 2004).  
A standardized approach to the clinical assessment of a musculoskeletal problem is 
suggested by Wolf and Akesson (2008): such a standardized approach will be conducted 
whether the patient is presenting to primary care, rheumatology or orthopedics. It also will 
provide a benchmark for this competency and can also be used as a teaching aid (Woolf and 
Åkesson 2008). The issue is whether this kind of standardization would be widely accepted 
by different displines or not. 
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SN 
RHEUMATOLOGICAL DISEASES (SKILLS COMPITENCIES) 
 
EXPERT 
RATING 
1 
To demonstrate competency skills in obtaining comprehensive history 
from patient with rheumatological disorders 
2.60 
2 
To demonstrate competency skills in applying general principle of joint 
examination ( screening exam, inspection, palpation, range of motion, 
& special tests) in musculoskeletal examination 
2.50 
3 
To demonstrate competency skills in performing comprehensive 
musculoskeletal examination including (the hands & wrists, elbows, 
shoulders, TMJ, the neck, spine & sacroiliac joints, knees, hips, ankles & 
feet).  
2.20 
4 To interpret the ANAs results 1.80 
5 
To interpret synovial fluid analysis results including polarized light 
microscopy 
1.70 
6 
To demonstrate competency skills in obtaining comprehensive history 
from patient with back pain.  
2.30 
7 To identify on plain x-ray of joints findings consistent with RA.  1.90 
8 To demonstrate competency skills in examining patient with RA.  2.30 
9 
To identify on plain x-ray findings consistent with 
spondyloarthropathies.  
1.70 
10 
To identify on plain x-ray findings consistent with crystal related joint 
disease.  
1.70 
11 To identify on plain x-ray findings consistent with JRA.  1.30 
12 
To demonstrate competency skills in examining patient with crystal-
related joint disease.  
1.60 
13 To demonstrate competency skills in examining patient with SLE.  2.30 
14 
To demonstrate competency skills in examining patient with 
scleroderma.  
1.80 
15 
To demonstrate competency skills in examining patient with rheumatic 
fever.  
2.30 
16 
To demonstrate competency skills in examining patient with soft tissue 
rheumatism.  
1.50 
17 
To demonstrate competency skills in obtaining comprehensive history 
from patients suspected to have vasculitis.  
2.00 
18 
To demonstrate competency skills in examining patient with nerve 
entrapment syndrome.  
1.70 
19 
To demonstrate competency skills in eliciting physical signs consistent 
with spondyloarthropathies.  
1.60 
20 To demonstrate competency skills in performing joint aspiration.  1.00 
 
Table 1. Rheumatological diseases (skills compitencies) 
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GALS (Gait, Arms, Legs and Spine) a locomotor screening  was developed and validated  as  
a rapid screening protocol / system for MSK with the aim for a quick identification of 
significant abnormalities (Doherty, Dacer et al. 1992). Various spectrums of health specialties 
could utilize this screening routine before specific examination and teach it to trainees and 
medical students. Tabe 3 represents a quick screening tool for MSK disorders adopted from 
(Woolf and Akesson 2008). 
 
KNOWLEDGE COMPETENCIES 
BREAKDOWN 
MEAN 
WEIGHTED 
RESPONSE 
NO.OF 
IDENTIFIED 
COMPETENCIES 
Approach To The Patient With Joint Pain 1.91 13 
Approach To The Patient With Low Back Pain 2.00 6 
Rheumatoid Arthritis 2.12 14 
Spondyloarthropathies(SpA) 1.89 17 
Crystal Related Joint Disease 1.95 16 
Osteoarthritis 2.36 7 
Bacterial Septic Arthritis 2.32 6 
Systemic Lupus Erythematosus 2.13 9 
Scleroderma 1.65 6 
Inflammatory Myopathies(Polymyositis 
&Dermatomyositis) 
1.69 7 
Sjogren’s Syndrome 1.65 4 
Vasculitis 1.78 8 
Juvenile Rheumatoid Arthritis (Juvenile Idiopathic 
arthritis) 
1.74 5 
Miscellaneous Syndromes 0.90 1 
TOTAL                                                                                                                       119 
Table 2. Disease Specific Ratings For Rheumatological Diseases 
3. Late onset SLE 
It is true that most SLE patients are in the child bearing age but SLE can occur in elderly. 
SLE has always been considered a disease of the young. Little attention has been given to 
late onset disease. In contrast with childhood disease, studies on elderly SLE patients are 
scarce (Boddaert, Huong et al. 2004). Late onset disease is the type of SLE whose 
manifestations begin after the age of 50 in majority of the studies (Boddaert, Huong et al. 
2004; Karoubi Nordon, Hayem et al. 2007; Rovensky and Tuchynova 2008) or after the age of 
65 (Pu, Luo et al. 2000).  SLE should be considered in the differential diagnosis while dealing 
with certain clinical settings in elderly population.  Clincians recognizing this clinical entity 
will help greatly to assure early diagnosis of SLE and avoid unnecessary delay in diagnosis 
and management.  
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Screening questions 
1 "Do you suffer from any pain or stiffness in your arms, legs, neck or back?" 
2 "Do you have any swelling of your joints?" 
3 "Do you have any difficulty with washing and dressing?" 
4 "Do you have any difficulty with going up or down stairs or steps?" 
Screening examination 
Gait 
Observe the patient walking forwards for a few meters, turning 
and walking back again. Recognize abnormalities of the different 
phases—heel strike, stance phase, toe-off and swing phases. 
Look for abnormalities of the movement of arms, pelvis, hips, 
knees, ankles and feet. 
Inspection of 
standing patient 
View the patient from the front, side and back, looking for any 
abnormalities, particularly of posture and symmetry. Apply 
pressure in the midpoint of each supraspinatus and roll an 
overlying skin fold to examine for tenderness. 
Spine 
Ask the patient to flex the neck laterally to each side. Place 
several fingers on the lumbar spinous processes and ask the 
patient to bend forward and attempt to touch their toes whilst 
standing with legs fully extended, observing for normal 
movement and feeling for expansion of space between spinous 
processes. 
Arms 
ask the patient to place both hands behind their head and then 
move elbows right back, then straighten the arms down the side 
of the body and bend elbows to 90° with palms down and 
fingers straight. Turn hands palms up and make a tight fist with 
each hand, then place, in turn, the tip of each finger onto the tip 
of the thumb. Squeeze the metacarpals from second to fifth 
cautiously for tenderness. 
Legs 
get the patient to recline on a couch, then flex, in turn, each hip 
and knee while holding and feeling the knee. Passively rotate the 
hip internally. With the leg extended and resting on the couch, 
press down on the patella while cupping it proximally to 
examine for tenderness or swelling of the knee. Squeeze all 
metatarsals and then inspect the soles of the feet for callosities. 
Table 3. Quick screening tool for msk disorder  
Overall, the incidence of late-onset SLE is low, but there are variable numbers reported in 
the literature, ranging from as low as 3.7% (Costallat and Coimbra 1994) and to as high as 
20.1% (Jacobsen, Petersen et al. 1998). This may be related to the different ethnic 
backgrounds included in the studies and the variable definitions of late-onset SLE. Most of 
the literature indicated that the sex ratio declines with age in SLE. In a pooled analysis of 714 
cases of late-onset SLE reported in the literature and 4700 young SLE patients, the female to 
male ratio observed with age in SLE was 4.4:1 vs. 10.6:1 respectively (Boddaert, Huong et al. 
2004). This probably reflects the relationship between SLE and estrogen status which decline 
in the elderly. 
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Late onset SLE is not a well studied disease and it has distinct clinical features. Although the 
disease activity and major organ involvement is less than in the early onset disease, it can 
cause more morbidity and mortality. In one study, there were significant number of patients 
with late onset SLE who died during the research period which may be related to the 
comorbidities and the use of medication which are age related  rather than the disease itself 
(Bertoli, Alarcon et al. 2006). Skin manifestations, photosensitivity, Raynaud phenomenon, 
arthritis, nephritis and neuropsychiatric manifestations were less frequent in comparison 
with young SLE patients. In late-onset SLE, a higher occurrence of pulmonary involvement, 
serositis, and Sjögren's syndrome were observed (Boddaert, Huong et al. 2004; Rovensky 
and Tuchynova 2008).  
There are variable findings in the literature about the occurrence of anti ds DNA antibodies 
in late-onset SLE (Padovan, Govoni et al. 2007; Rovensky and Tuchynova 2008). These 
antibodies did not correlate with organ complications of late-onset disease in one study 
(Padovan, Govoni et al. 2007). A higher prevalence of rheumatoid factor, anti-Ro and anti-La 
antibodies were observed in late-onset SLE. However, lower prevalence of anti-RNP 
antibodies and hypocomplementemia were observed as well (Maddison 1987; Belostocki 
and Paget 2002; Boddaert, Huong et al. 2004; Padovan, Govoni et al. 2007).  
In general, late onset SLE is characterized by a lower disease activity (Costallat and Coimbra 
1994; Boddaert, Huong et al. 2004). This fact does not exclude significant morbidity 
associated with it. The seriuosness of some clinical presentations may preclude clinicians 
from considering autoimmune diseases as an etiology in their work up. This may result in 
unncessary delay in diagnosing late onset SLE. We reported a case of late onset SLE in a 65 
year old female patient, previously healthy, who presented with progressive paraplegia and 
sensory level at T4 (Almoallim, Bukhari et al. 2009). MRI showed extensive transverse 
myelitis (TM) involving the thoracic spine. Antinuclear antibodies (ANA), anti-double 
stranded DNA antibodies (Anti ds DNA) and lupus anticoagulant were all positive. The 
diagnosis was delayed for a month after hospital admission due to lack of awareness of 
basic work up to diagnose SLE. Obviously, SLE was not considered in the basic differential 
diagnosis of this patient. What had been required was simply considering SLE as a possible 
etiology then ordering ANA as a screening tool for SLE. 
4. Neuropsychiatric manifestations of SLE (NPSLE)  
NPSLE may still present a very difficult diagnostic challenge for clinicians (Joseph, Lammie 
et al. 2007). Neurologic features at the onset of SLE is regarded rare, occurring only in 
approximately 3% in some studies and up to 24% in others (Joseph, Lammie et al. 2007). 
NPSLE affects more than half of SLE patients. It ranges in severity from mild symptoms like 
headache to severe neurological dysfunction. Clinicians particularly general internists and 
neurologists who are dealing primarily with patients presenting with complex neurological 
presentations should consider autoimmune diseases and particularly SLE in their diffrential 
diagnosis. Awarness of the 19 neuropsychiatric syndromes defined by ACR as an associated 
feature with NPSLE is essential. (See corresponding chapters for further details). 
The most prevalent symptoms are headache, seizures, mood disorders and cerebrovascular 
disease. Regarding headaches, data showed that there was no significant difference in the 
prevalence of tension type headache and migraine between the SLE patient and the general 
population (Mitsikostas, Sfikakis & Goadsby, 2004).  
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Simple or complex attention, memory, reasoning, executive skills, language, visual-spatial 
processing and psychomotor speed are normal cognitive functions, and any significant 
deficit in one or all of these functions is defined as cognitive dysfunction by ACR. These 
dysfunctions are usually underestimated and require careful testing to avoid unnecessary 
delay in diagnosis.  
Guillain-Barre syndrome (GBS), myasthenia gravis (MG), plexus injury, TM, aseptic 
meningitis and autonomic dysfunctions are less frequent and rare neurological 
manifestation associated with SLE. GBS is an acute, rapidly progressive, autoimmune 
demylinating polyneuropathy resulting in symmetric, ascending paralysis that can be severe 
involving the respiratory muscles and require mechanical ventilation. This disease is 
relatively rare among SLE patients as it is only associated in 7 out of 1100 GBS cases in an 
early study (Leneman 1966). MG is another autoimmune disorder affecting the proximal, 
bulbar and extraocular muscles due to antibodies directed against the post synaptic 
acetylcholine receptors resulting in weakness of the muscles. Among 78 patients with this 
disease, 6 patients (7.7%) had SLE (Sthoeger, Neiman et al. 2006). It was concluded in this 
study that MG patients should be evaluated for the coexistence of SLE, and assessment for 
MG is suggested in lupus patients with unexplained muscular weakness. Various case 
reports showed the association between them (Vaiopoulos, Sfikakis et al. 1994; Bhinder, 
Majithia et al. 2006). The prevalence of TM in SLE patients is 1-2% (Kovacs, Lafferty et al. 
2000). It can occur as the initial manifestation of SLE in up to 39% or within the first five 
years of a diagnosis of SLE in 42% of the total patient population analyzed in one study 
(Kovacs, Lafferty et al. 2000). The predominant presentation of TM in SLE is a sensory level 
commonly in the thoracic region, spastic paraparesis and sphincter disturbance (Kovacs, 
Lafferty et al. 2000; D'Cruz, Mellor-Pita et al. 2004). TM as a presenting feature of late onset 
SLE is rare. Few cases were reported; one patient out of 15 in a report of TM as a presenting 
feature for SLE (D'Cruz, Mellor-Pita et al. 2004), two patients out of 14 in an older series 
about TM in SLE (Kovacs, Lafferty et al. 2000) and two case reports (Chen, Lai et al. 2004; 
Almoallim, Bukhari et al. 2009). 
5. How to avoid delay in diagnosis and management of renal  
involvment in SLE? 
Lupus nephritis (LN) is one of the most worrisome and potentially serious complication of 
SLE and a delay in rcognition and treatment of LN lead to significant morbidity and 
mortality. LN occurs in 40 to 70% of SLE patients (Cameron,1999a; Seligman et al, 2002) 
especially in the first year after diagnosis during the first three months (Eilertsen et al,2011). 
Early searching for renal involvment in SLE is crucial to prevent it from progression. The 
goal of clinicians taking care of lupus patients is to identify individuals with signs of early 
renal disease who are at risk for renal damage.  Appropriate treatment can be initiated early 
to prevent inflammatory lesions from progression to sclerotic ones (end stage LN).  
There are simple parameters that should be followed in each clinical visit to pick up  
early  disease. Clinicians should monitor blood pressure, urine analysis and possibly  
renal function test and anti ds DNA antibodies in each clinical visit. The following are 
abnormal parameters that suggest renal involvement and mandate biopsy: elevated anti ds 
DNA antibodies and decreased C4 were more commonly seen in proliferative lupus 
nephritis compared with non proliferative lupus nephritis (Wen, 2011), hematuria (>5 red 
blood cells per high power field on urine microscopy), nephrotic (>3.5 g protein/24hrs) or 
www.intechopen.com
 
Systemic Lupus Erythematosus 
 
228 
subnephrotic range proteinuria (>0.5g protein/24hrs),or protein/creatinine ratio (>1.0), 
casts (>5 haemogranular or red blood cast), elevated urea and creatinine and elevated blood 
pressure (BP>140/90 mmHg). 
There is a clear need to consider kidney biopsy early on in the course of the disease to help 
guide therapy and suggest long term prognosis. Kidney biopsy can determine the degree 
and severity of renal involvment through established histopathological guidelines. 
Determining the stage of kidney disease have a signigicant impact on determining response 
to therapy. Most nephrologists agree that kidney biopsy is worthwhile in SLE patients with 
abnormal urine analysis and/or reduced renal function. They suggest that kidney biopsy 
should be performed as soon as clinical signs of renal involvment are evident in order to 
accelerate treatment decisions and minimize risk of inflamation induced irreversible renal 
damage (Contreras et al, 2002). Delaying kidney biopsy is unfortunately a practice that is 
still observed among some rheumatologists and nephrologists. Lack of adequately trained 
nephrologists/radiologists who can perform kidney biopsy safely might be a factor that 
explains this delay. Less frequent follow up visits for lupus patients due to overwhelmed 
rheumatology practices in some parts of the world is another possible factor. Poor 
monitoring,  inadequate control of lupus disease activity, and lack of awareness of the need 
to consider kidney biopsy are all other possible factors.  
It was demonstrated early on in the literature in a cohort of 87 patients with LN that delay 
between the detection of the onset of renal disease and renal biopsy was a significant 
predictor at the time of a first renal biopsy for subsequent renal insufficiency (relative risk 
4.9; 95% confidence interval 1.7 to 14.5; p < 0.001) and death due to lupus renal involvement 
(relative risk 6.7; 95% confidence interval 2.1 to 21.2; p < 0.001) (Esdaile, Joseph et al. 1994). 
Delaying therapy, because of presumably mild disease, is often associated with increased 
glomerular injury and fibrosis and therefore a lesser response to immunosuppressive drugs 
(Esdaile, Joseph et al. 1994). Several other recent studies reported that a delay in renal 
biopsy(and therapy) is a strong independent predictor of poor outcome in LN (Faurscho et 
al,2006; Fiehn et al, 2003). Sometimes significant renal disease (stage 3, 4 and 5) can be found 
in renal biopsy even in the absence of impired renal function or even in the presence of low 
level of protienuria (urine:protien/creatinine ratio < 1.0)(Christopher-Stine et al, 2006). A 
full discussion on issues related to kidney biopsy in SLE is presented in another chapter in 
this book. 
5.1 Control of risk factors in lupus nephritis 
An important goal for proper medical care for lupus patient, particularly from a renal 
perspective is the control of risk factors such as protienuria, hypertension, dyslipidemia and 
diet control. 
5.1.1 Proteinuria and hypertension 
Heavy proteinuria is a common feature of patients with proliferative LN and progressive 
renal impairment (Dubois et al, 1987). Serial studies by the Stanford group demonstrated 
that heavy proteinuria is a predictor of progressive renal impairment (Buckheit et al, 1997). 
Therefore, reduction of proteinuria independent of reduction in blood pressure is associated 
with subsequent beneficial effect on the progression of renal disease (Lewis et al, 1993; 
Maschio et al, 1996; Petersen et al, 1995; The Gisen Group 1997). Early intervention on 
proteinuria has a major impact in preventing the progression of kidney disease in SLE. 
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Aggressive reduction of proteinuria should be a goal for any clinician taking care of LN 
patients.  
A number of reports indicated that aggressive treatment of hypertension inhibits 
progressive renal injury (Petersen et al, 1995; Brazy et al, 1990; Rosansky et al, 1990). Few 
mmHg reduction in blood pressure value does matter on the long term. The hypertension 
detection and follow-up programs showed that patients whose BP was 129/86 mmHg 
versus 130/90 mmHg had greater preservation of renal function (Shulman et al, 1989). It 
should be recognized that hypertension is also a strong risk factor for developing 
atherosclerosis which lead to increased risk of heart attacks and strokes. This is to add to the 
extreme importance of controlling hypertension in lupus patients.  
5.1.2 Dyslipidemia 
Dyslipidemia is a common feature of lupus patients treated with steroids and also with 
progressive renal injury and nephrotic syndrome. There is a strong relation in LN patients 
between cholesterol concentration and proteinuria. There are several reports in non-diabetic 
renal disease with proteinuria that relate increase cholesterol and triglyceride to an increase 
in loss of renal function (Apperloo, de Zeeukw & de Jong,1994; Maschio et al, 1989; 
Samuelsson et al, 1993). Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors 
(statins) are beneficial in lowering low density lipoprotien (LDL) cholesterol. Fish oils and 
fibric acid analogs are helpful in lowering triglyceride and raising high density lipoprotien 
(HDL) cholesterol and should be considered in patients with dyslipidemia. Again, it is 
hoped that this issue should not be neglected by clinicians taking care of lupus patients. 
5.2 The role of angiotensin converting enzyme inhibitors in patients with  
lupus nephritis 
Angiotensen converting enzyme inhibitors (ACEI) represent a class of drugs used to treat 
many common diseases like hypertension, heart failure, post myocardial infarction, and 
microalbuminuria in diabetic patients and nowadays is also used in SLE for many purposes. 
They work by inhibiting the angiotensin converting enzyme that is responsible for 
converting angiotensin 1 to angiotensin 2. ACEI have an anti-inflamatory property as 
angiotensin 2 has pro-inflamatory effect on the cells of different organ system. ACE  has 
been found to be high in synovial fluid (Veal et al, 1992) and rheumatoid nodule in 
rheumatoid arthritis patients (Goto et al, 1992) which suggest its role in the inflammation. In 
SLE patients, ACEI have an end organ protection effect by its multiple effects on 
hypertension and protienuria. ACEI delay the occurence of renal involvment and are 
associated with decreased risk of disease activity in patients with SLE (Duran-Barragan  et 
al, 2008). This is an impressive and important finding that should alert all clinicans taking 
care of lups patients to be aware of this valuable effect on patients outcome. Every effort 
should be spent to assure that LN patients are maintained on these drugs. Lupus patients 
are chronic steroid users which make them liable for hypertension, diabetes mellitus (DM) 
,and coronary artery disease (CAD). Numerous studies have shown beneficial effects of 
using ACEI in the management and prevention of these conditions. Unfortunately, many 
clinicians including rheumatologists tend not to use ACEI/ARBs (angiotensin receptors 
blockers) commonly in SLE patients or they delay introducing them early in the course of 
the disease. One possible reason for this delay is that physicians tend to focus more on acute 
and dramatic presentations of SLE rather than monitoring risk factors that would show 
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benefical effects on the long term. Therefore, a comprehensive approach to care for lupus 
patients should be followed. 
6. Cardiovascular involvement in SLE 
SLE is associated with a variety of cardiovascular manifestations; some are life threatening 
(including myocardial infarction)  and others are much less serious. Threre are several risk 
factors for heart related conditions, many of which can be avoided. Cardiovascular disease 
is a major cause of morbidity and mortality in SLE. 
Pericarditis remains the most common cardiovascular disease in SLE and occur in 12- 48% 
(Moder, Miller & Tazelaar, 1999). It should be included in the differential diagnosis of SLE 
patients presenting with shortness of breath, low grade fever,pleuritic chest pain and/or dry 
cough. ANA test should be ordered for any young lady in childbearing age with pleuritic 
chest pain. This is to avoid delaying the diagnosis of SLE as pericarditis can be a presenting 
feature. Other less frequent cardiac manifestations of SLE are myocrditis (which is usually 
silent), endocarditis with one characteristic but rare presentation as Libman-Sack 
endocarditis known as verrucous non bacterial thrombotic endocarditis, valvular disease, 
arrhythmias, pulmonary hypertension, and systemic hypertension. 
6.1 SLE and accelarated atherosclerosis 
Today with SLE patients living longer due to more effective drug therapies, CAD has 
become a leading cause of late mortality in SLE. Women with aged 35-44 were found to 
have 50 times more risk of myocardial infarctions than aged matched  controls (Mazni et al, 
1997). Several case-control studies, both autopsy studies and myocardial perfusion studies 
have consistently shown a 30-40% prevelance of sub-clinical CAD in SLE patient (Korkmaz, 
Cansu & Kasifoqlu, 2007). Despite an increasing appreciation of the importance of 
cardiovascular disease in SLE, recognition of traditional risk factors have been noted to be 
suboptimal. As an example, in one academic rheumatology practice, deficits in knowledge 
and management of cardiac risk factors were observed among both SLE patients and their 
physicians (Costenbader et al, 2004). This is again to emphasize the point of increase 
awareness of this serious issue in lupus patients. Lack of comprehensive approach to care 
for SLE patients may lead to significant delay in diagnosing a reversible cardiac risk factor. 
Obviously, this will result in delay in management and increase in cardiac morbidity and 
mortality. 
Many cases with SLE have evidence of subclinical accelerated atherosclerosis (figure 1). It 
is related to both traditional and non traditional risk factors for CAD. The traditional risk 
factors are demographics, family history, smoking, hypertension, DM, and dyslipidemia, 
while the non traditional risk factors include chronic inflammation, presence of 
autoantibodies, prolonged vascular inflamation, corticosrteroid use (10 mg change in 
prednisolone lead to change in mean arterial pressure of 1.1 mmHg after adjustment for 
age,  weight and antihypertensive drug use, and 10 mg increase in prednisolone was 
associated with a mean weight change of 5.50 ±1.23 (Petri, 2000)), renal disease and 
antiphospholipd antibodies. One factor that has repeatedly been shown to affect the 
prevelance of CAD in SLE is active disease. Appropriate management of active SLE is one 
of the best preventitive measures. Due to the high prevelance of CAD in SLE patient, SLE 
itself should be viewed as a CAD risk factor in the same way as DM is (Bradley, 2009; 
Shah, Shah & Krishnan, 2009). 
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SLE patients should have an annual fasting blood glucose and a urinalysis at every clinic 
visit to assess for protienuria, glucosuria and hematuria. Patients with evidence of impaired 
glucose tolerance should undergo dietary changes to prevent frank diabetes from 
developing. Blood pressure(BP) should be followed at every clinical visit with a goal BP of 
less than 130/80 mmHg. For prehypertensive patients, the physician first should try 
therapeutic lifestyle changes (exercise and diet modification) and assess renal function. If 
blood pressure is consistently above 140/90 mmHg, despite therapeutic lifestyle changes, 
then antihypertensive medications should be started with prefarable drugs such as ACEI. 
The cholesterol recommandation for lupus patients are more stringent than those for the 
average patients. Lupus patients should have an annual fasting lipid profile with a goal  
LDL <100 mg/dl (<2.6 mmol/L) (Wajed et al, 2004).  Statin therapy is indicated for LDL>130 
mg/dl (> 3.4 mmol/L) even in those without traditional CAD risk factors. Statins have been 
shown to directly improve endothelial function even in patient with normal lipid profile 
(Vaughan et al, 2000; Laufs et al, 1998).  Also, these patients should be counseled on 
smoking cessation and weight reduction if their BMI >25. Low dose aspirin should be 
considered for those patients with traditional risk factors and those that are 
antiphospholipid antibody positive (Erkan et al, 2002;  Bertsias et al, 2008; Wahl et al, 2000). 
Screening patients at higher risk by non invasive techniques like carotid Duplex or Single 
Photon Emission Computed Tomography-Dual Isotope Myocardial Perfusion Imaging 
(SPECT-DIMPI) can help in early detection of subclinical atherosclerosis (Sella et al, 2003). 
To prevent long-term cardiovascular consequences, these patients should be treated 
aggressively, both to control their primary lupus disease activity and to minimize 
modifiable CAD risk factors. Life style modification, weight reduction, statins for 
hyperlipidemia, controlling blood pressure, controlling DM and minimizing the 
glucocorticoids use all these can minimize the CAD in SLE patients. 
 
 
Fig. 1. Two-stage model of accelerated atherosclerosis in SLE (Petri, 2000) 
7. The role of antimalarial drugs in SLE  
Currently, there is over-emphasis from many international authorities in SLE on the need to 
maintain all lupus patients on antimalarial drugs (AMD). This is based on the abundance of 
data that confirm their huge beneficial effects in SLE. They are one of the most widely 
tolerated medications used in the treatment of SLE since 1955 (Scherbel, Schuchter & 
Harrison, 1957; Tye et al, 1959). They are safe even during pregnancy. Like any other 
medication, they have their side effects. However, an antimalarial drug like 
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hydroxychloroquine (HCQ) on a daily low dose has no or mild side effects and serious 
complications are rare. Ocular toxicity is the most important toxicity of HCQ, so regular 
ophthalmological check up is important. Chloroquine is found to have more side effects 
than hydroxychloroquine. Nowadays, AMD are not only used for patients with organ 
damage or patients with active disease but they are essential and key treatment for all 
patients with SLE. They should be started alone or with other medications once the 
diagnosis is made. A recent data showed the beneficial effects not only on the disease itself 
but on many other factors. For this reason, AMD should never be stopped in patients with 
SLE. Over the last decades many studies were done on AMD (especially HCQ) and it 
showed that HCQ has an effect in lowering fasting glucose and calculated insulin resistance 
(Penn et al, 2010) and reducing insulin degradation (Smith et al, 1987). There is significant 
reduction in total cholesterol, triglyceride (TG), LDL and very low density 
lipoprotein(VLDL) and significant increase in high density lipoprotein (HDL) level among 
patients using AMD and prednisolone than those with prednisolone alone (Borba & Bonfa, 
2001; Rahman, 1999; Tam et al, 2000 ). As the HCQ showed its effect on glycemic control and 
lipid profile, it might decrease the risk for atherosclerosis.  In addition, HCQ inhibits platelet 
aggregation and adhesion (Petri, 1996) so it is a mild anticoagulant and can decrease the risk 
of thrombosis (both arterial and venous) in patients with SLE (Kaiser, Cleveland & Criswell, 
2009; Wallace, 1987) but this effect is still under trials. Data showed protective effect of HCQ 
on the BMD especially on the spine (Mok, Mak & Ma, 2005). Lupus activity was significantly 
reduced among patients who were using HCQ, and can reach up to 50% in some studies 
(Ruiz-Irastorza et al, 2010). It has positive impact on the survival and can protect against 
irreversible organ damage. As SLE and other rheumatological diseases affect female in child 
bearing age and they will have concerns regarding taking medications during pregnancy. 
HCQ does not appear to have effect on the fetus and it is not associated with any congenital 
anomalies. In addition data showed that its use during pregnancy decreases lupus activity. 
Other non-rheumatological specialities like nephrology and obstetrics and gynaecology may 
underestimate the clinical value of continuing AMD in all SLE patients. LN patients who are 
followed exclusively by nephrologists are not maintained on HCQ as observed in some 
centres unfortunately. This is probably because some believe that HCQ is not considered as 
one of the standard therapies for LN. However, AMD are standard therapies for SLE. 
8. Rare manifestations of SLE 
One of the approaches to avoid delay in SLE diagnosis and management is to recognize rare 
presentations of SLE. Fever of unknown origin is an example of this. Fever by itself is very 
common in SLE. It may affect up to 50% of SLE patients as a sign of active disease (Petri, 
2002). Patients with SLE frequently develop abnormalities in one or more of the three blood 
cell lines. Awareness of different hematological abnormalities affecting SLE patients is 
essential. The association between idiopathic thrombocytopenic purpura (ITP), thrombotic 
thrombocytopenic purpura (TTP) and SLE should be noted. Rare entities like Kikuchi-
Fujimoto’s disease (KFD) or histiocytic necrotizing lymphadenitis (a benign, self-limited 
disease of unknown etiology which affects mainly young women, characterized by localized 
lymphadenopathy, predominantly in the cervical region, fever and leukopenia) has been 
reported in association with SLE. It can present before, at the same time, or after the clinical 
appearance of KFD (Boddaert, Huong et al. 2004). 
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8.1 Kikuchi-Fujimoto disease 
Kikuchi-Fujimoto disease (KFD) or Necrotizing Lymphadenitis is a rare, benign, self-limited 
disease that was first reported in Japan in 1972. It affects the female predominantly with 
female to male ratio 4:1 (Al Salloum, 1998; Dorfman, 1987; Lopez et al, 2000). It usually 
resolves spontaneously between one and four months (Santana et al, 2005) and up to six 
months in another study (Kucukardali et al, 2007). Although it is benign, there are reported 
cases of disease progression and mortality rate can reach up to 2.1% (Kucukardali et al, 
2007).  KFD is found to be associated with many comorbid diseases; SLE was the most 
frequently associated with it. Among 224 cases with KFD, 32 of them had SLE. Of these, 
eighteen (56%) had both diseases together, six (19%) developed SLE later, four (12%) already 
had SLE previously and four (12%) had incomplete SLE as they did not  meet the ACR 
criteria for SLE (Kucukardali, Solmazgul et al. 2007).  
8.2 Thrombotic Thrombocytopenia Purpura (TTP) 
TTP is a life threatening condition in which there is platelet aggregation that result in 
microangiopathic haemolytic anaemia (MAHA) and thrombocytopenia. It presents with the 
pentad of MAHA, thrombocytopenia, fever, acute renal failure and neurological 
manifestations. SLE is one of its secondary causes and it correlates with disease activity 
(Cheung, 2006) but rarely occurs as a first manifestation although there was a reported case in 
which a patient was diagnosed to have TTP and SLE simultaneously (Vasoo, Thumboo & 
Fong, 2002). Making the diagnosis of TTP in SLE patient is difficult as classical TTP symptoms 
may be due to SLE disease activity. The diagnosis of TTP can be established by the presence of 
thrombocytopenia, fragmented red blood cells (schistocytes) in blood film, increase billirubin 
and lactate dehydrogenase, high urea and creatinine, normal coagulation profile and negative 
Coomb’s test. It is important to rule out other serious conditions like disseminated 
intravascular coagulation (DIC) and intracranial haemorrhage (thrombocytopenia and 
neurological manifestation) by ordering coagulation profile and CT head respectively. The 
hallmark of TTP is detection fragmented RBC’s in blood film. It is mandatory to have a 
peripheral smear conducted in any SLE patient presenting with new onset of anemia and 
thrombocytopenia. It is obvious that early diagnosis and aggressive treatment can make a 
huge difference in outcome.  
8.3 Immune Thrombocytopenic Purpura (ITP) 
ITP is a disease characterized by the presence of antibodies against platelets. This results in 
early clearance of platelets particularly by the spleen, and decreases their life span from 7-10 
days to few hours. It presents by symptoms related to decrease platelet count as petechial 
haemorrhage, easy bruising, gum bleeding or epistaxis and menorrhagia in women. 
Intracranial bleeding is rare. ITP is a diagnosis of exclusion as more serious conditions like 
haematological malignancies must be ruled out first especially in people more than 60 years 
of age. It is characterized by presence of low platelet and normal haemoglobin and white 
blood cells count (WBC) except if there is concomitant iron deficiency anaemia or anaemia 
of chronic disease, normal PT and PTT, decrease platelet or presence of giant platelet in 
peripheral blood film and increase the number of megakaryocyte in bone marrow. An 
association between ITP and SLE has been recognized for decades and it can be the first 
manifestation in some patients with SLE (Jun, et al, 2008; Mestanza-Peralta et al, 1997). It has 
been estimated that 3-15% of patients with apparently isolated ITP go on to develop SLE 
(Karpatkin, 1980). 
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8.4 Fever of Unknown Origin (FUO) 
FUO is a documented fever of >38˚C on several occasions, for> 3 weeks without reaching 
the diagnosis after the initial diagnostic workup (Abdelbaky et al., 2011). FUO remains an 
important health problem that requires demanding efforts in order to reach the diagnosis 
despite the presence of advanced technology. Infections, connective tissue diseases, 
neoplasms are major causes that should be first ruled out before thinking about other 
causes. It was shown that among 100 patients with FUO, 50% were found to have infections, 
24% were found to have connective tissue diseases (33.3% of them diagnosed as SLE, 20.8% 
familial Mediterranian fever, 16.6% rheumatoid arthritis, 12.5% Still’s disease & rheumatic 
fever and 4.3% Behcet’s disease/ Chron’s disease), no cause was identified in 11%, while the 
remaining 8% and 7% were found to have miscellaneous causes and neoplasia respectively 
(Abdelbaky et al, 2011).  
 
How to avoid delay in SLE 
diagnosis and management? 
Action plan 
1. Consider SLE in the differential 
diagnosis of multisystemic 
presentations. 
 Order screening ANA. 
2. Assure screening for MSK 
abnormalities in all acutely ill 
patients. 
 Ask about joint pain, swelling and 
morning stiffness. 
 Perform simple active range of 
motion test as a screening tool for 
MSK abnormalities. 
3. Be aware of neurological 
manifestations of SLE (seizure, 
stroke, TM, MG, GBM, etc). 
 
 Include in your work-up 
screening ANA. 
 Educate clinicians taking care of 
neurological diseases about this. 
 
4. Be aware of CAD risk factors in 
SLE patients 
 
 Life style modifications, weight 
reduction, check BP in every clinic 
visit, annual fasting blood 
glucose, statins for 
LDL>130mg/dl, 
 
5. to decrese disease activity and 
possibly to decrease the risk of 
atherosclerosis. 
 Maintain all patients on HCQ 
6. Fever is common in SLE and it 
might be a presenting feature.  Order screening ANA. 
7. Be aware of different 
hematological abnormalities 
related to SLE (cytopenias, ITP, 
KFD, TTP). 
 Order screening ANA. 
 Order peripheral smear for any 
SLE patient with new onset 
anemia and thrombocytopenia. 
8. SLE can still affect elderly 
population. 
 Order screening ANA as 
appropriate to the clinical 
presentation. 
 Educate clinicians taking care of 
elderly patients about this. 
Table 4. Some recommended steps to avoid delay in SLE diagnosis and management 
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9. Conclusion 
We discussed in this chapter several issues that can face clinicians in their daily work with 
SLE patients. Our aim was to focus on how to prevent delay in SLE diagnosis and 
management. Table 4 represents some recommended steps that might help in this regard. 
Enhancing MSK examination skills among clinicans in general is an international concern. 
This clearly will result in early detection of patients with clinical evidence of arthritis 
including SLE. There are several clinical settings and presentations where SLE should be 
considered. Late-onset SLE can affect elderly patients with few differences than classical 
SLE patients. NPSLE represents a diagnositic challenge to clinicians. There are 19 
neuropsychiatric syndromes defined by ACR as an associated feature with NPSLE.  Delay 
in considering kidney biopsy in SLE patients once indicated results in poor renal 
outcomes. Adjusting risk factors for renal disease like proteinuria, hypertension and 
dyslipidemia is vaguely considered by some clinicans. The leading cause of mortality in 
SLE is cardiac. Clinicans taking care of SLE patients should put prevention of cardiac 
morbidities and mortalities an important goal in their management agenda. With new 
modalities of treatment and the wide use of AMD since 1955 there is significant 
improvement in survival and quality of life in patients with SLE. Therefore, all lupus 
patients should be maintained on AMD like HCQ. SLE can present initially with a variety 
of hematological maifestations like ITP , TTP and KFD. SLE should be in the differenrtial 
diagnosis of FUO.  
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